Century Therapeutics (IPSC) Gets a Buy from Mizuho Securities
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Salim Syed maintained a Buy rating on Century Therapeutics (IPSC) with an $8.00 price target. This follows H.C. Wainwright's August 13 report, which also reiterated a Buy rating but set a lower $5.00 price target. The coverage highlights analyst opinions within the healthcare sector.
Mizuho Securities analyst Salim Syed maintained a Buy rating on Century Therapeutics today and set a price target of $8.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Syed covers the Healthcare sector, focusing on stocks such as Century Therapeutics, Amgen, and Biogen. According to TipRanks, Syed has an average return of 1.6% and a 44.33% success rate on recommended stocks.
In a report released on August 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.